Cytotoxic and anticancer activities of isatin and its derivatives: A comprehensive review from 2000-2008

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 4, 2009, Pages 397-414

  Vine, Kara L ^a   Matesic, L ^a   Locke, J M ^a   Ranson, M ^a   Skropeta, D ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

2,3 dioxindole; Anticancer; Cytotoxicity; Enzyme inhibitor; Indolinone; Isatin; Kinase; Tubulin

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; 5 [(5 FLUORO 1,2 DIHYDRO 2 OXO 3H INDOL 3 YLIDENE)METHYL] N (2 HYDROXY 3 MORPHOLINOPROPYL) 2,4 DIMETHYL 1H PYRROLE 3 CARBOXAMIDE; 5,7 DIBROMO N (4 METHYLBENZYL)ISATIN; AMINOMETHYLENE LYSINE ISATIN DERIVATIVE; ANTINEOPLASTIC METAL COMPLEX; ARYLIDENE ISATIN DERIVATIVE; BIBF 1120; COMBRETASTATIN A4; CYCLIN DEPENDENT KINASE 2; DOCETAXEL; DUOCARMYCIN DERIVATIVE; FLUOROURACIL; GATIFLOXACIN; INDIGO CARMINE; INDIRUBIN; ISATIN; ISATIN AMINOACETYLHYDRAZONE DERIVATIVE; ISATIN DERIVATIVE; ISATIN HYDRAZONE DERIVATIVE; ISOINDIGO; N NAPHTHYL ISATIN DERIVATIVE; N PHENACYL 5,7 DIBROMOISATIN DERIVATIVE; N PHENETHYL ISATIN DERIVATIVE; PACLITAXEL; PYRINDAMYCIN A; PYRINDAMYCIN B; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE;

ANTINEOPLASTIC ACTIVITY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CYTOTOXICITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENTIATION; HUMAN; IC 50; LUNG NON SMALL CELL CANCER; NONHUMAN; PROTEIN PHOSPHORYLATION; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; DRUG ANTAGONISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; HUMANS; ISATIN; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67649804836     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520610909040397     Document Type: Review

References (148)

1. Erdmann, O.L. Untersuchungen uber den Indigo. J. Prakt. Chem., 1840, 19(1), 321-362.
2. Laurent, A. Recherches sur l'indigo. Ann. Chim. Phys., 1840, 3(3), 393-434.
3. Guo, Y.; Chen, F. Zhongcaoyao, 1986, 17(8), 104.
4. Bergman, J.; Lindström, J.O.; Tilstam, U. The structure and properties of some indolic constituents in Couroupita guianensis aubl. Tetrahedron, 1985, 41(14), 2879-2881.
5. Wei, L.; Wang, Q.; Liu, X. Application of thin-layer chromatography in quality control of Chinese medicinal preparations. II. Qualitative analysis of some Chinese medicinal preparations of Chansu. Yaowu Fenxi Zazhi, 1982, 2(288), CA 98:95726b
6. Kapadia, G.J.; Basak, S.P.; Shukla, Y.N.; Fales, H.M.; Sokoloski, E.A. Potential carcinogens.10. Melosatins, novel isatin alkaloids from Melochia-tomentosa roots. J. Nat. Prod., 1976, 39(6), 471.
7. Kapadia, G.J.; Shukla, Y.N.; Basak, S.P.; Sokoloski, E.A.; Fales, H.M. Potential carcinogens.13. The melosatins - a novel class of alkaloids from Melochia-tomentosa. Tetrahedron, 1980, 36(17), 2441-2447.
8. Ansaasamoah, R.; Kapadia, G.J.; Lloyd, H.A.; Sokoloski, E.A. Picratidine, a new indole alkaloid from Picralima nitida seeds. J. Nat. Prod., 1990, 53(4), 975-977.
9. Grafe, U.; Radics, L. Isolation and structure elucidation of 6-(3′-methyl-buten-2′-yl)isatin, an unusual metabolite from Streptomyces-Albus. J. Antibiot., 1986, 39(1), 162-163.
10. Schunck, E. Notes on the purple of the ancients. 1. The chromogen of Purpura capillus. 2. Properties of the colouring matter formed by insolation from the chromogen of Purpura capillus. J. Chem. Soc., 1879, 35, 589-596.
11. Letellier, A. Recherches sur la pourpre produite par le Purpura lapillus. Arch. Zool. Exp. Gen., 2nde ser., 1890, 8, 361-403.
12. Baker, J.T.; Sutherland, M.D. Pigments of marine animals. VIII. Precursors of 6,6′-dibromoindigotin (tyrian purple) from the mollusc Dicathais orbita gmelin. Tetrahedron Lett., 1968, 9(1), 43-46.
13. Benkendorff, K.; Bremner, J.B.; Davis, A.R. Indole derivatives from the egg masses of Muricid molluscs. Molecules, 2001, 6(2), 70-78.
14. Hamaue, N.; Yamazaki, N.; Minami, M.; Endo, T.; Hirafuji, M.; Monma, Y.; Togashi, H.; Saito, H.; Parvez, S.H. Effect of isatin, an endogenous MAO inhibitor, on acetylcholine and dopamine levels in the rat striatum. Biog. Amines, 1999, 15(3), 367-377.
15. Gillam, E.M.J.; Notley, L.M.; Cai, H.L.; De Voss, J.J.; Guengerich, F.P. Oxidation of indole by cytochrome P450 enzymes. Biochemistry, 2000, 39(45), 13817-13824.
16. Pandeya, S.N.; Smitha, S.; Jyoti, M.; Sridhar, S.K. Biological activities of isatin and its derivatives. Acta. Pharm., 2005, 55(1), 27-46.
17. Medvedev, A.; Igosheva, N.; Crumeyrolle-Arias, M.; Glover, V. Isatin: role in stress and anxiety. Stress, 2005, 8(3), 175-183.
18. Medvedev, A.; Buneeva, O.; Glover, V. Biological targets for isatin and its analogues: implications for therapy. Biologics Targets Ther., 2007, 1(2), 151-162.
19. Clark, R.J.H.; Cooksey, C.J.; Daniels, M.A.M.; Withnall, R. Indigo, woad, and Tyrian Purple: important vat dyes from antiquity to the present. Endeavour, 1993, 17(4), 191-199.
20. Cooksey, C.J. Tyrian Purple: 6,6′-dibromoindigo and related compounds. Molecules, 2001, 6(9), 736-739.
21. Ferreira, E.S.B.; Hulme, A.N.; McNab, H.; Quye, A. The natural constituents of historical textile dyes. Chem. Soc. Rev., 2004, 33(6), 329-336.
22. Sumpter, W.C. The chemistry of isatin. Chem. Rev., 1944, 34(3), 393-434.
23. Popp, F.D.; Katritzky, A.R.; Boulton, A.J. In Advances in Heterocyclic Chemistry; Academic Press, 1975, Vol. 18, pp. 1-58.
24. Sumpter, W.C. The chemistry of oxindole. Chem. Rev., 1945, 37(3), 443-479.
25. Ivashchenko, A.V.; Dziomko, V.M. Reactions of isatin and its derivatives with aromatic and heterocyclic ortho-diamines. Uspekhi Khimii, 1977, 46(2), 228-238.
26. Shvekhgeimer, M.G.A. Synthesis of heterocyclic compounds by the cyclization of isatin and its derivatives (review). Chem. Heterocycl. Compd. (Engl. Transl.), 1996, 32(3), 249.
27. Joshi, K.C.; Joshi, R. Isatin: a versatile molecule for the synthesis of novel spiroheterocycles. J. Indian Chem. Soc., 1999, 76(11-12), 643-649.
28. Silva, J.F.M.d.; Garden, S.J.; Pinto, A.C. The chemistry of isatins: a review from 1975 to 1999. J. Braz. Chem. Soc., 2001, 12(3), 273-324.
29. Abele, E.; Abele, R.; Dzenitis, O.; Lukevics, E. Indole and isatin oximes: synthesis, reactions, and biological activity. Chem. Heterocycl. Compd., 2003, 39(1), 3-35.
30. Karpenko, A.; Shibinskaya, M.; Zholobak, N.; Olevinskaya, Z.; Lyakhov, S.; Litvinova, L.; Spivak, M.; Andronati, S. Synthesis, DNA-binding, and interferon-inducing properties of isatin and benzoisatin hydrazones. Pharm. Chem. J., 2006, 40(11), 595-602.
31. Harris, P.A. Oxindole Inhibitors of Cyclin-Dependent Kinases as Anti-Tumor Agents; Taylor and Francis Group: Boca Raton FL, USA, 2007.
32. Cerchiaro, G.; Ferreira, A.M.d.C. Oxindoles and copper complexes with oxindole-derivatives as potential pharmacological agents. J. Braz. Chem. Soc., 2006, 17(8), 1473-1485.
33. Cane, A.; Tournaire, M.C.; Barritault, D.; Crumeyrolle-Arias, M. The endogenous oxindoles 5-hydroxyoxindole and isatin are antiproliferative and proapoptotic. Biochem. Biophys. Res. Commun., 2000, 276(1), 379-384.
34. Vine, K.L.; Locke, J.M.; Ranson, M.; Benkendorff, K.; Pyne, S.G.; Bremner, J.B. In vitro cytotoxicity evaluation of some substituted isatin derivatives. Bioorg. Med. Chem., 2007, 15(2), 931-938.
35. Vine, K.L.; Locke, J.M.; Ranson, M.; Pyne, S.G.; Bremner, J.B. An investigation into the cytotoxicity and mode of action of some novel N-alkyl-substituted isatins. J. Med. Chem., 2007, 50(21), 5109-5117.
36. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell, 2000, 100(1), 57-70.
37. Sun, L.; Tran, N.; Tang, F.; App, H.; Hirth, P.; McMahon, G.; Tang, C. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J. Med. Chem., 1998, 41(14), 2588-2603.
38. Bacher, G.; Nickel, B.; Emig, P.; Vanhoefer, U.; Seeber, S.; Shandra, A.; Klenner, T.; Beckers, T. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res., 2001, 61(1), 392-399.
39. Gastpar, R.; Goldbrunner, M.; Marko, D.; von Angerer, E. Methoxy-substituted 3-formyl-2-phenylindoles inhibit tubulin polymerization. J. Med. Chem., 1998, 41(25), 4965-4972.
40. Beckers, T.; Reissmann, T.; Schmidt, M.; Burger, A.M.; Fiebig, H.H.; Vanhoefer, U.; Pongratz, H.; Hufsky, H.; Hockemeyer, J.; Frieser, M.; Mahboobi, S. 2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors. Cancer Res., 2002, 62(11), 3113-3119.
41. Beckers, T.; Mahboobi, S. Natural, semisynthetic and synthetic microtubule inhibitors for cancer therapy. Drugs Future, 2003, 28, 767-785.
42. Brancale, A.; Silvestri, R. Indole, a core nucleus for potent inhibitors of tubulin polymerization. Med. Res. Rev., 2007, 27(2), 209-238.
43. Gaeta, F.C.A.; Galan, A.A.; Kraynack, E.A. Telomerase inhibitors. PCT/ US99/13523. 1999.
44. Motzer, R.J.; Michaelson, M.D.; Redman, B.G.; Hudes, G.R.; Wilding, G.; Figlin, R.A.; Ginsberg, M.S.; Kim, S.T.; Baum, C.M.; DePrimo, S.E.; Li, J.Z.; Bello, C.L.; Theuer, C.P.; George, D.J.; Rini, B.I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 2006, 24(1), 16-24.
45. Prenen, H.; Cools, J.; Mentens, N.; Folens, C.; Sciot, R.; Schoffski, P.; Van Oosterom, A.; Marynen, P.; Debiec-Rychter, M. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin. Cancer. Res., 2006, 12(8), 2622-2627.
46. Hossain, M.M.; Islam, N.; Khan, R.; Islam, R. Cytotoxicity study of dimethylisatin and its heterocyclic derivatives. Bangladesh J. Pharmacol., 2007, 2(2), 66-70.
47. Igosheva, N.; Lorz, C.; O'Conner, E.; Glover, V.; Mehmet, H. Isatin, an endogenous monoamine oxidase inhibitor, triggers a dose- and time-dependent switch from apoptosis to necrosis in human neuroblastoma cells. Neurochem. Int., 2005, 47(3), 216-224.
48. Nguyen, J.T.; Wells, J.A. Direct activation of the apoptosis machinery as a mechanism to target cancer cells. Proc. Natl. Acad. Sci. USA, 2003, 100(13), 7533-7538.
49. Liu, Y.; Lashuel, H.A.; Choi, S.; Xing, X.; Case, A.; Ni, J.; Yeh, L.A.; Cuny, G.D.; Stein, R.L.; Lansbury, P.T., Jr. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem. Biol., 2003, 10(9), 837-846.
50. Bacher, G.; Nickel, B.; Emig, P.; Vanhoefer, U.; Seeber, S.; Shandra, A.; Klenner, T.; Beckers, T. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res., 2001, 61(1), 392-399.
51. Liu, Y.; Lashuel, H.A.; Choi, S.; Xing, X.; Case, A.; Ni, J.; Yeh, L.A.; Cuny, G.D.; Stein, R.L.; Lansbury, P.T., Jr. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem. Biol., 2003, 10(9), 837-846.
52. Sasaki, H.; Yukiue, H.; Moriyama, S.; Kobayashi, Y.; Nakashima, Y.; Kaji, M.; Fukai, I.; Kiriyama, M.; Yamakawa, Y.; Fujii, Y. Expression of the protein gene product 9.5, PGP9.5, is correlated with T-status in non-small cell lung cancer. Jpn. J. Clin. Oncol., 2001, 31(11), 532-535.
53. Bittencourt Rosas, S.L.; Caballero, O.L.; Dong, S.M.; da Costa Carvalho Mda, G.; Sidransky, D.; Jen, J. Methylation status in the promoter region of the human PGP9.5 gene in cancer and normal tissues. Cancer Lett., 2001, 170(1), 73-79.
54. Yamazaki, T.; Hibi, K.; Takase, T.; Tezel, E.; Nakayama, H.; Kasai, Y.; Ito, K.; Akiyama, S.; Nagasaka, T.; Nakao, A. PGP9.5 as a marker for invasive colorectal cancer. Clin. Cancer Res., 2002, 8(1), 192-195.
55. Matesic, L.; Locke, J.M.; Bremner, J.B.; Pyne, S.G.; Skropeta, D.; Ranson, M.; Vine, K.L. N-phenethyl and N-naphthylmethyl isatins and analogues as in vitro cytotoxic agents. Bioorg. Med. Chem., 2008, 16(6), 3118-3124.
56. Li, P.K.; Xiao, Z.; Hu, Z.; Pandit, B.; Sun, Y.; Sackett, D.L.; Werbovetz, K.; Lewis, A.; Johnsamuel, J. Conformationally restricted analogs of Combretastatin A-4 derived from SU5416. Bioorg. Med. Chem. Lett., 2005, 15(24), 5382-5835.
57. Chen, Z.; Merta, P.J.; Lin, N.H.; Tahir, S.K.; Kovar, P.; Sham, H.L.; Zhang, H. A-432411, a novel indolinone compound that disrupts spindle pole formation and inhibits human cancer cell growth. Mol. Cancer Ther., 2005, 4(4), 562-568.
58. Damiens, E.; Baratte, B.; Marie, D.; Eisenbrand, G.; Meijer, L. Anti-mitotic properties of indirubin-3′-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene, 2001, 20(29), 3786-3797.
59. Leclerc, S.; Garnier, M.; Hoessel, R.; Marko, D.; Bibb, J.A.; Snyder, G.L.; Greengard, P.; Biernat, J.; Wu, Y.Z.; Mandelkow, E.M.; Eisenbrand, G.; Meijer, L. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem., 2001, 276(1), 251-260.
60. Davis, S.T.; Benson, B.G.; Bramson, H.N.; Chapman, D.E.; Dickerson, S.H.; Dold, K.M.; Eberwein, D.J.; Edelstein, M.; Frye, S.V.; Gampe Jr, R.T.; Griffin, R.J.; Harris, P.A.; Hassell, A.M.; Holmes, W.D.; Hunter, R.N.; Knick, V.B.; Lackey, K.; Lovejoy, B.; Luzzio, M.J.; Murray, D.; Parker, P.; Rocque, W.J.; Shewchuk, L.; Veal, J.M.; Walker, D.H.; Kuyper, L.F. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science, 2001, 291(5501), 134-137.
61. Bramson, H.N.; Corona, J.; Davis, S.T.; Dickerson, S.H.; Edelstein, M.; Frye, S.V.; Gampe, R.T., Jr.; Harris, P.A.; Hassell, A.; Holmes, W.D.; Hunter, R.N.; Lackey, K.E.; Lovejoy, B.; Luzzio, M.J.;
62. Montana, V.; Rocque, W.J.; Rusnak, D.; Shewchuk, L.; Veal, J.M.; Walker, D.H.; Kuyper, L.F. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis. J. Med. Chem., 2001, 44(25), 4339-4358.
63. Lane, M.E.; Yu, B.; Rice, A.; Lipson, K.E.; Liang, C.; Sun, L.; Tang, C.; McMahon, G.; Pestell, R.G.; Wadler, S. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res., 2001, 61(16), 6170-6177.
64. Doble, B.W.; Woodgett, J.R. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci., 2003, 116(7), 1175-1186.
65. Wakefield, J.G.; Stephens, D.J.; Tavare, J.M. A role for glycogen synthase kinase-3 in mitotic spindle dynamics and chromosome alignment. J. Cell Sci., 2003, 116(4), 637-646.
66. Goold, R.G.; Gordon-Weeks, P.R. Microtubule-associated protein 1B phosphorylation by glycogen synthase kinase 3beta is induced during PC12 cell differentiation. J. Cell. Sci., 2001, 114(23), 4273-4274.
67. Imahori, K.; Uchida, T. Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J. Biochem., 1997, 121(2), 179-188.
68. Mandelkow, E.M.; Mandelkow, E. Tau in Alzheimer's disease. Trends Cell Biol., 1998, 8(11), 425-427.
69. Vine, K.L. An investigation into the cytotoxic properties of isatin-derived compounds: potential for use in targeted cancer therapy. Doctor of Philosophy, University of Wollongong, 2007.
70. Leclerc, S.; Garnier, M.; Hoessel, R.; Marko, D.; Bibb, J.A.; Snyder, G.L.; Greengard, P.; Biernat, J.; Wu, Y.Z.; Mandelkow, E.M.; Eisenbrand, G.; Meijer, L. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease - A property common to most cycline-dependent kinase inhibitors? J. Biol. Chem., 2001, 276(1), 251-260.
71. Potterat, O.; Hamburger, M. In Progress in Drug Research, Natural Compounds as Drugs; Petersen, F.; Amstutz, R., Eds.; Birkhaeuser, 2008, Vol. 1, pp. 62-64.
72. Hoessel, R.; Leclerc, S.; Endicott, J.A.; Nobel, M.E.; Lawrie, A.; Tunnah, P.; Leost, M.; Damiens, E.; Marie, D.; Marko, D.; Niederberger, E.; Tang, W.; Eisenbrand, G.; Meijer, L. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell. Biol., 1999, 1(1), 60-67.
73. Jautelat, R.; Brumby, T.; Schafer, M.; Briem, H.; Eisenbrand, G.; Schwahn, S.; Kruger, M.; Lucking, U.; Prien, O.; Siemeister, G. From the insoluble dye indirubin towards highly active, soluble CDK2-inhibitors. Chembiochem, 2005, 6(3), 531-540.
74. Marko, D.; Schatzle, S.; Friedel, A.; Genzlinger, A.; Zankl, H.; Meijer, L.; Eisenbrand, G. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br. J. Cancer, 2001, 84(2), 283-289.
75. Meijer, L.; Shearer, J.; Bettayeb, K.; Ferandin, Y. Diversity of the intracellular mechanisms underlying the anti-tumor properties of indirubins. Int. Congress Ser., 2007, 1304, 60-74.
76. Eisenbrand, G.; Hippe, F.; Jakobs, S.; Muehlbeyer, S. Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine. J. Cancer Res. Clin. Oncol., 2004, 130(11), 627-635.
77. Sethi, G.; Ahn, K.S.; Sandur, S.K.; Lin, X.; Chaturvedi, M.M.; Aggarwal, B.B. Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-kappa B signaling pathway. J. Biol. Chem., 2006, 281(33), 23425-23435.
78. Adachi, J.; Mori, Y.; Matsui, S.; Takigami, H.; Fujino, J.; Kitagawa, H.; Miller, C.A.; Kato, T.; Saeki, K.; Matsuda, T. Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J. Biol. Chem., 2001, 276(34), 31475-31478.
79. Spink, B.C.; Hussain, M.M.; Katz, B.H.; Eisele, L.; Spink, D.C. Transient induction of cytochromes P450 1A1 and 1B1 in MCF-7 human breast cancer cells by indirubin. Biochem. Pharmacol., 2003, 66(12), 2313-2321.
80. Polychronopoulos, P.; Magiatis, P.; Skaltsounis, A.L.; Myrianthopoulos, V.; Mikros, E.; Tarricone, A.; Musacchio, A.; Roe, S.M.; Pearl, L.; Leost, M.; Greengard, P.; Meijer, L. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J. Med. Chem., 2004, 47(4), 935-946.
81. Wang, F.Z.; Fang, Y.C.; Zhu, T.J.; Zhang, M.; Lin, A.Q.; Gu, Q.Q.; Zhu, W.M. Seven new prenylated indole diketopiperazine alkaloids from holothurian-derived fungus Aspergillus fumigatus. Tetrahedron, 2008, 64(34), 7986-7991.
82. Gerby, B.; Boumendjel, A.; Blanc, M.; Bringuier, P.P.; Champelovier, P.; Fortune, A.; Ronot, X.; Boutonnat, J. 2-Arylidenedi-hydroindole-3-ones: design, synthesis, and biological activity on bladder carcinoma cell lines. Bioorg. Med. Chem. Lett., 2007, 17(1), 208-213.
83. Kudo, S.; Kashida, H.; Tamura, T.; Kogure, E.; Imai, Y.; Yamano, H.; Hart, A.R. Colonoscopic diagnosis and management of nonpolypoid early colorectal cancer. World J. Surgery, 2000, 24(9), 1081-1090.
84. Hurlstone, D.P.; Fujii, T.; Lobo, A.J. Early detection of colorectal cancer using high-magnification chromoscopic colonoscopy. Br. J. Surgery, 2002, 89(3), 272-282.
85. Boger, D.L.; Johnson, D.S. Cc-1065 and the duocarmycinsunraveling the keys to a new class of naturally derived DNA alkylating-agents. Proc. Natl. Acad. Sci. USA, 1995, 92(9), 3642-3649.
86. Boger, D.L.; Johnson, D.S. CC-1065 and the duocarmycins: Understanding their biological function through mechanistic studies. Angew. Chem.-Int. Ed., 1996, 35(13-14), 1438-1474.
87. Searcey, M. Duocarmycins - Nature's Prodrugs? Curr. Pharm. Des., 2002, 8, 1375-1389.
88. Pevarello, P.; Villa, M. Cyclin-dependent kinase inhibitors: a survey of the recent patent literature. Expert Opin. Ther. Pat, 2005, 15(6), 675-703.
89. Andreani, A.; Granaiola, M.; Leoni, A.; Locatelli, A.; Morigi, R.; Rambaldi, M.; Garaliene, V.; Welsh, W.; Arora, S.; Farruggia, G.; Masotti, L. Antitumor activity of new substituted 3-(5-imidazo [2,1-b]thiazolylmethylene) -2-indolinones and study of their effect on the cell cycle. J. Med. Chem., 2005, 48(17), 5604-5607.
90. Chen, Z.H.; Merta, P.J.; Lin, N.H.; Tahir, S.K.; Kovar, P.; Sham, H.L.; Zhang, H.Y. A-432411, a novel indolinone compound that disrupts spindle pole formation and inhibits human cancer cell growth. Mol. Cancer Ther., 2005, 4(4), 562-568.
91. Shiraishi, T.; Domoto, T.; Imai, N.; Shimada, Y.; Watanabe, K. Specific inhibitors of tyrosine-specific protein kinase, synthetic 4-hydroxycinnamamide derivatives. Biochem. Biophys. Res. Commun., 1987, 147(1), 322-328.
92. Griffith, R.; Brown, M.N.; McCluskey, A.; Ashman, L.K. Small molecule inhibitors of protein kinases in cancer - how to overcome resistance. Mini-Rev. Med. Chem., 2006, 6(10), 1101-1110.
93. Atkins, M.; Jones, C.A.; Kirkpatrick, P. Sunitinib maleate. Nat. Rev. Drug Discov., 2006, 5(4), 279-280.
94. Izzedine, H.; Buhaescu, I.; Rixe, O.; Deray, G. Sunitinib malate. Cancer Chemother. Pharmacol., 2007, 60(3), 357-364.
95. Krystal, G.W.; Honsawek, S.; Kiewlich, D.; Liang, C.; Vasile, S.; Sun, L.; McMahon, G.; Lipson, K.E. Indoline tyrosine kinase inhbitors block Kit activation and growth of small cell lung cancer cells. Cancer Res., 2001, 61(9), 3660-3668.
96. Li, X.; Huang, P.; Cui, J.J.; Zhang, J.; Tang, C. Novel pyrrolyllactone and pyrrolyllactam indolinones as potent cyclin-dependent kinase 2 inhibitors. Bioorg. Med. Chem. Lett., 2003, 13(11), 1939-1942.
97. Li, H.-H.; Zhang, X.-H.; Tan, J.-Z.; Chen, L.-L.; Liu, H.; Luo, X.-M.; Shen, X.; Lin, L.-P.; Chen, K.-X.; Ding, J.; Jiang, H.-L. Design, synthesis, antitumor evaluations and molecular modeling studies of novel 3,5-substituted indolin-2-one derivatives. Acta Pharmacol. Sin., 2007, 28(1), 140-152.
98. Gao, N.; Kramer, L.; Rahmani, M.; Dent, P.; Grant, S. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)- meth-(Z)-ylidene]-5-methoxy-1,3- dihydroindol-2-one (SU9516) kills human leukemia cells via downregulation of Mcl-1 through a transcriptional mechanism. Mol. Pharmacol., 2006, 70(2), 645-655.
99. Braud, E.; Duflos, M.; Nourrisson, M.-R.; Tonnerre, A.; Picot, C.; Le Baut, G.; Renard, P.; Pfeiffer, B.; Tucker, G. Potential inhibitors of angiogenesis. Part I: 3-(imidazol-4(5)-ylmethylene)indolin-2-ones. J. Enzym. Inhib. Med. Chem., 2003, 18(3), 243-252.
100. Li, P.-K.; Xiao, Z.; Hu, Z.; Pandit, B.; Sun, Y.; Sackett, D.L.; Werbovetz, K.; Lewis, A.; Johnsamuel, J. Conformationally Restricted Analogs of Combretastatin A-4 Derived from SU5416. Bioorg. Med. Chem. Lett., 2005, 15, 5382-5385.
101. Pandit, B.; Sun, Y.; Chen, P.; Sackett, D.L.; Hu, Z.; Rich, W.; Li, C.; Lewis, A.; Schaefer, K.; Li, P.-K. Structure-activity-relationship studies of conformationally restricted analogs of Combretastatin A-4 derived from SU5416. Bioorg. Med. Chem., 2006, 14(19), 6492-6501.
102. Laird, A.D.; Vajkoczy, P.; Shawver, L.K.; Thurnher, A.; Liang, C.; Mohammadi, M.; Schlessinger, J.; Ullrich, A.; Hubbard, S.R.; Blake, R.A.; Fong, T.A.T.; Strawn, L.M.; Sun, L.; Tang, C.; Hawtin, R.; Tang, F.; Shenoy, N.; Hirth, P.K.; McMahon, G.; Cherrington, J.M. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res., 2000, 60(15), 4152-4160.
103. Klenke, F.M.; Abdollahi, A.; Bertl, E.; Gebhard, M.-M.; Ewerbeck, V.; Huber, P.E.; Sckell, A. Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo. BMC Cancer, 2007, 7, 49.
104. Sun, L.; Liang, C.; Shirazian, S.; Zhou, Y.; Miller, T.; Cui, J.; Fukada, J.Y.; Chu, J.-Y.; Nematalla, A.; Wang, X.; Chen, H.; Sistla, A.; Luu, T.C.; Tang, F.; Wei, J.; Tang, C. Discovery of 5-[5-fluoro-2 -oxo-1,2-dihydroindol- (3Z)-ylidenemethyl]- 2,4-dimethyl-1 H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem., 2003, 46(7), 1116-1119.
105. Patyna, S.; Laird, A.D.; Mendel, D.B.; O'Farrell, A.-M.; Liang, C.; Guan, H.; Vojkovsky, T.; Vasile, S.; Wang, X.; Chen, J.; Grazzini, M.; Yang, C.Y.; Haznedar, J.O.; Sukbuntherng, J.; Zhong, W.-Z.; Cherrington, J.M.; Hu-Lowe, D. SU14813: A novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol. Cancer Ther., 2006, 5(7), 1774-1782.
106. Islam, I.; Bryant, J.; Chou, Y.-L.; Kochanny, M.J.; Lee, W.; Phillips, G.B.; Yu, H.; Adler, M.; Whitlow, M.; Ho, E.; Lentz, D.; Polokoff, M.A.; Subramanyam, B.; Wu, J.M.; Zhu, D.; Feldman, R.I.; Arnaiz, D.O. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: Design, synthesis and biological activity. Bioorg. Med. Chem. Lett., 2007, 17(14), 3814-3818.
107. Islam, I.; Brown, G.; Bryant, J.; Hrvatin, P.; Kochanny, M.J.; Phillips, G.B.; Yuan, S.; Adler, M.; Whitlow, M.; Lentz, D.; Polokoff, M.A.; Wu, J.; Shen, J.; Walters, J.; Ho, E.; Subramanyam, B.; Zhu, D.; Feldman, R.I.; Arnaiz, D.O. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: Optimization of BX-517. Bioorg. Med. Chem. Lett., 2007, 17(14), 3819-3825.
108. Wood, E.R.; Kuyper, L.; Petrov, K.G.; Hunter III, R.N.; Harris, P.A.; Lackey, K. Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles. Bioorg. Med. Chem. Lett., 2004, 14(4), 953-957.
109. Zhu, G.-D.; Gandhi, V.B.; Gong, J.; Luo, Y.; Liu, X.; Shi, Y.; Guan, R.; Magnone, S.R.; Klinghofer, V.; Johnson, E.F.; Bouska, J.; Shoemaker, A.; Oleksijew, A.; Jarvis, K.; Park, C.; De Jong, R.; Oltersdorf, T.; Li, Q.; Rosenberg, S.H.; Giranda, V.L. Discovery and SAR of oxindole-pyridine-based protein kinase B/Akt inhibitors for treating cancers. Bioorg. Med. Chem. Lett., 2006, 16(13), 3424-3429.
110. Kulimova, E.; Oelmann, E.; Bisping, G.; Kienast, J.; Mesters, R.M.; Schwable, J.; Hilberg, F.; Roth, G.J.; Munzert, G.; Stefanic, M.; Steffen, B.; Brandts, C.; Muller-Tidow, C.; Kolkmeyer, A.; Buchner, T.; Serve, H.; Berdel, W.E. Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors. Mol. Cancer Ther., 2006, 5(12), 3105-3112.
111. Hilberg, F.; Roth, G.J.; Krssak, M.; Kautschitsch, S.; Sommergruber, W.; Tontsch-Grunt, U.; Garin-Chesa, P.; Bader, G.; Zoephel, A.; Quant, J.; Heckel, A.; Rettig, W.J. BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res., 2008, 68(12), 4774-4782.
112. Rizzi, E.; Cassinelli, G.; Dallavalle, S.; Linzi, C.; Cincinelli, R.; Nannei, R.; Cuccuru, G.; Zunino, F. Synthesis and RET protein kinase inhibitory activity of 3-arylureidobenzylidene-indolin-2-ones. Bioorg. Med. Chem. Lett., 2007, 17(14), 3962-3968.
113. Sassatelli, M.; Bouchikhi, F.; Messaoudi, S.; Anizon, F.; Debiton, E.; Barthomeuf, C.; Prudhomme, M.; Moreau, P. Synthesis and antiproliferative activities of diversely substituted glycosyl-isoindigo derivatives. Eur. J. Med. Chem., 2006, 41(1), 88-100.
114. Gursoy, A.; Karali, N. Synthesis and primary cytotoxicity evaluation of 3 (3-phenyl-4-(3H)-quinazolinone-2-yl)mercaptoacetyl]-hydrazono]-1 H-2-indolinones. Eur. J. Med. Chem., 2003, 38(6), 633-643.
115. Lawrence, H.R.; Pireddu, R.; Chen, L.; Luo, Y.; Sung, S.-S.; Szymanski, A.M.; Yip, M.L.R.; Guida, W.C.; Sebti, S.M.; Wu, J.; Lawrence, N.J. Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds. J. Med. Chem., 2008, 51(16), 4948-4956.
116. Juranic, Z.; Anastasova, F.; Juranic, I.; Stanojkovic, T.; Radulovic, S.; Vuletic, N. Antiproliferative action of isatine-beta-thiocarbo-hydrazone and N-ethylisatine-beta-thiocarbohydrazone on human PBMC and on two neoplastic cell lines. J. Exp. Clin. Cancer Res., 1999, 18(3), 317-324.
117. Pirrung, M.C.; Pansare, S.V.; Das Sarma, K.; Keith, K.A.; Kern, E.R. Combinatorial optimization of isatin-beta-thiosemicarbazones as anti-poxvirus agents. J. Med. Chem., 2005, 48(8), 3045-3050.
118. Pervez, H.; Iqbal, M.S.; Tahir, M.Y.; Nasim, F.-U.-H.; Choudhary, M.I.; Khan, K.M. In vitro cytotoxic, antibacterial, antifungal and urease inhibitory acitivities of some N4-substituted isatin-3-thiosemicarbazones. J. Enzym. Inhib. Med. Chem., 2008, 23(6), 848-854.
119. Pervez, H.; Chohan, Z.H.; Ramzan, M.; Nasim, F.-U.-H.; Khan, K.M. Synthesis and biological evaluation of some new N4-substituted isatin-3-thiosemicarbazones. J. Enzym. Inhib. Med. Chem., 2008, In press.
120. Karali, N. Synthesis and primary cytotoxicity evaluation of new-5-nitroindole-2,3-dione derivatives. Eur. J. Med. Chem., 2002, 37(11), 909-918.
121. Karali, N.; Terzioglu, N.; Gursoy, A. Synthesis and primary cytotoxicity evaluation of new 5-bromo-3-substituted-hydrazono-1H-2-indolinones. Arch. Pharm., 2002, 335(8), 374-380.
122. Eshba, N.H.; Salama, H.M. 5-(2-Oxo-3-indolinylidene)thiazoli-dine-2,4-dione-1,3-di-Mannich base derivatives: synthesis and evaluation for antileukemic activity. Pharmazie, 1985, 40(5), 320-322.
123. Yogeeswari, P.; Sriram, D.; Kavya, R.; Tiwari, S. Synthesis and in-vitro cytotoxicity evaluation of Gatifloxacin Mannich bases. Biomed. Pharmacother., 2005, 59(9), 501-510.
124. Abadi, A.H.; Abou-Seri, S.M.; Abdel-Rahman, D.E.; Klein, C.; Lozach, O.; Meijer, L. Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents. Eur. J. Med. Chem., 2006, 41(3), 296-305.
125. Jarrahpour, A.; Khalili, D.; De Clercq, E.; Salmi, C.; Brunel, J.M. Synthesis, antibacterial, antifungal and antiviral activity evaluation of some new bis-Schiff bases of isatin and their derivatives. Molecules, 2007, 12(8), 1720-1730.
126. Linder, M.C. Copper and genomic stability in mammals. Mutat. Res. Fundam. Mol. Mech. Mugag., 2001, 475(1-2), 141-152.
127. Cerchiaro, G.; Aquilano, K.; Filomeni, G.; Rotilio, G.; Ciriolo, M.R.; Ferreira, A.M. Isatin-Schiff base copper(II) complexes and their influence on cellular viability. J. Inorg. Biochem., 2005, 99(7), 1433-1440.
128. Filomeni, G.; Cerchiaro, G.; Da Costa Ferreira, A.M.; De Martino, A.; Pedersen, J.Z.; Rotilio, G.; Ciriolo, M.R. Pro-apoptotic activity of novel isatin-Schiff base copper(II) complexes depends on oxidative stress induction and organelle-selective damage. J. Biol. Chem., 2007, 282(16), 12010-12021.
129. Sathisha, M.P.; Revankar, V.K.; Pai, K.S.R. Synthesis, structure, electrochemistry, and spectral characterization of bis-isatin thiocarbohydrazone metal complexes and their antitumor activity against Ehrlich ascites carcinoma in Swiss albino mice. Metal-Based Drugs, 2008, 2008: 362105.
130. Chohan, Z.H.; Shaikh, A.U.; Naseer, M.M. Metal-based isatin-bearing sulfonamides: their synthesis, characterization and biological properties. Appl. Organomet. Chem., 2006, 20(11), 729-739.
131. Karki, S.S.; Thota, S.; Darj, S.Y.; Balzarini, J.; De Clercq, E. Synthesis, anticancer, and cytotoxic activities of some mononuclear Ru(II) compounds. Bioorg. Med. Chem., 2007, 15(21), 6632-6641.
132. Mazumder, U.K.; Gupta, M.; Karki, S.S.; Bhattacharya, S.; Rathinasamy, S.; Thangavel, S. Synthesis, anticancer and antibacterial activity of some novel mononuclear Ru(II) complexes. Chem. Pharm. Bull., 2004, 52(2), 178-185.
133. Sassatelli, M.; Bouchikhi, F.; Messaoudi, S.; Anizon, F.; Debiton, E.; Barthomeuf, C.; Prudhomme, M.; Moreau, P. Synthesis and antiproliferative activities of diversely substituted glycosyl-isoindigo derivatives. Eur. J. Med. Chem., 2006, 41, 88-100.
134. Sassatelli, M.; Bouchikhi, F.; Aboab, B.; Anizon, F.; Fabbro, D.; Prudhomme, M.; Moreau, P. In vitro antiproliferative activities and kinase inhibitory potencies of glycosyl-isoindigo derivatives. Anti-Cancer Drugs, 2007, 18, 1069-1074.
135. Bouchikhi, F.; Anizon, F.; Moreau, P. Synthesis and antiproliferative activities of isoindigo and azaisoindigo derivatives. Eur. J. Med. Chem., 2008, 43, 755-762.
136. Xiao, Z.; Hao, Y. In Indirubin, the Red Shade of Indigo; Meijer, L.; Guyard, N.; Skaltsounis, L.A.; Eisenbrand, G., Eds.; Life in Progress Editions: Roscoff, France, 2006, pp. 203-208.
137. Wang, L.K.; Mencher, S.K. In Indirubin, the Red Shade of Indigo; Meijer, L.; Guyard, N.; Skaltsounis, L.A.; Eisenbrand, G., Eds.; Life in Progress Editions: Roscoff, France, 2006, pp. 247-258.
138. Xiao, Z.; Qian, L.; Liu, B.; Hao, Y. Meisoindigo for the treatment of chronic myelogenous leukemia. Br. J. Haematol., 2000, 111, 711-712.
139. Xiao, Z.; Hao, Y.; Liu, B.; Qian, L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leukemia Lymphoma, 2002, 43, 1763-1768.
140. Xiao, Z.; Wang, Y.; Lu, L.; Li, Z.; Peng, Z.; Han, Z.; Hao, Y. Anti-angiogenesis effects of meisoindigo on chronic myelogenous leukemia in vitro. Leukemia Res., 2006, 30, 54-59.
141. Marti, C.; Carreira, E.M. Construction of spiro[pyrrolidine-3,3′-oxindoles] - recent applications to the synthesis of oxindole alkaloids. Eur. J. Org. Chem., 2003, (12), 2209-2219.
142. Kitajima, M.; Nakamura, T.; Kogure, N.; Ogawa, M.; Mitsuno, Y.; Ono, K.; Yano, S.; Aimi, N.; Takayama, H. Isolation of gelsidine-type indole alkaloids from Gelsenium elegans and evaluation of the cytotoxic activity of Gelsemium alkaloids for A431 epidermoid carcinoma cells. J. Nat. Prod., 2006, 69(4), 715-718.
143. Franz, A.K.; Dreyfuss, P.D.; Schreiber, S.L. Synthesis and cellular profiling of diverse organosilicon small molecules. J. Am. Chem. Soc., 2007, 129(5), 1020-1021.
144. Raunak; Kumar, V.; Mukherjee, S.; Poonam; Prasad, A.K.; Olsen, C.E.; Schaffer, S.J.C.; Sharma, S.K.; Watterson, A.C.; Errington, W.; Parmar, V.S. Microwave mediated synthesis of spiro-(indoline-isoxazolidines): mechanistic study and biological activity evaluation. Tetrahedron, 2005, 61(23), 5687-5697.
145. Yong, S.R.; Ung, A.T.; Pyne, S.G.; Skelton, B.W.; White, A.H. Synthesis of novel 3 '-spirocyclic-oxindole derivatives and assessment of their cytostatic activities. Tetrahedron, 2007, 63(25), 5579-5586.
146. Natarajan, A.; Fan, Y.-h.; Chen, H.; Guo, Y.; Iyasere, J.; Harbinski, F.; Christ, W.J.; Aktas, H.; Halperin, J.A. 3,3-Diaryl-1,3-dihydroindol-2-ones as antiproliferatives mediated by translation initiation inhibition. J. Med. Chem., 2004, 47(8), 1882-1885.
147. Anonymous. Withdrawal of oxyphenisatin acetate, diacetoxydiphenolisatin and triacetyldiphenolisatin from Australian market. Med. J. Aust., 1972, 1(20), 1051-1053.
148. Uddin, M.K.; Reignier, S.G.; Coulter, T.; Montalbetti, C.; Granas, C.; Butcher, S.; Krog-Jensen, C.; Fielding, J. Syntheses and anti-proliferative evaluation of oxyphenisatin derivatives. Bioorg. Med. Chem. Lett., 2007, 17(10), 2854-2857.